Arcadia Q1 2024 revenue up 2% YoY; net loss narrows to $2.4M from $9.4M

Arcadia Biosciences, Inc.

2024-Q1 EPS reported -$1.78 revenue$1,255,000

Product revenue $1.255M (+2% YoY); fifth consecutive quarter with >30% gross margin.
Loss from continuing ops improved 21% to $3.064M; lowest in 6 years.
Net loss $2.423M ($1.78/share) vs $9.384M ($10.86/share) in Q1 2023, helped by absence of PIPE valuation loss.
GoodWheat in 3,500+ stores; Zola added ~200 stores in Q1, set to ship to ~1,300 more in Q2.
Cash & short-term investments $8.5M; operating cash burn $3.21M in quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcadia Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.